Agenus Inc (NASDAQ:AGEN) – Research analysts at B. Riley issued their Q3 2019 earnings estimates for shares of Agenus in a research report issued on Wednesday, August 14th. B. Riley analyst H. Polishetty anticipates that the biotechnology company will earn ($0.52) per share for the quarter. B. Riley has a “Buy” rating and a $5.00 price objective on the stock. B. Riley also issued estimates for Agenus’ Q4 2019 earnings at ($0.30) EPS, FY2019 earnings at ($1.06) EPS, FY2020 earnings at ($0.98) EPS, FY2021 earnings at ($0.67) EPS, FY2022 earnings at ($0.56) EPS and FY2023 earnings at ($0.31) EPS.
Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.05). The business had revenue of $15.72 million for the quarter, compared to analyst estimates of $5.37 million.
Separately, BidaskClub downgraded shares of Agenus from a “sell” rating to a “strong sell” rating in a research report on Friday, July 26th.
Shares of Agenus stock opened at $2.83 on Monday. The company’s fifty day simple moving average is $2.58 and its two-hundred day simple moving average is $2.82. The company has a market cap of $380.36 million, a P/E ratio of -1.97 and a beta of 1.86. Agenus has a 12-month low of $1.54 and a 12-month high of $3.88.
Several large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp lifted its position in Agenus by 26.6% during the 4th quarter. Bank of New York Mellon Corp now owns 442,886 shares of the biotechnology company’s stock worth $1,055,000 after buying an additional 92,957 shares in the last quarter. Geode Capital Management LLC lifted its position in Agenus by 34.1% during the 4th quarter. Geode Capital Management LLC now owns 1,062,200 shares of the biotechnology company’s stock worth $2,528,000 after buying an additional 269,890 shares in the last quarter. Bank of America Corp DE lifted its position in Agenus by 111.8% during the 4th quarter. Bank of America Corp DE now owns 150,367 shares of the biotechnology company’s stock worth $358,000 after buying an additional 79,364 shares in the last quarter. MetLife Investment Advisors LLC bought a new stake in Agenus during the 4th quarter worth about $110,000. Finally, Metropolitan Life Insurance Co. NY bought a new stake in Agenus during the 4th quarter worth about $80,000. 33.39% of the stock is currently owned by hedge funds and other institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.